Pain relief after robot-assisted knee replacement for knee osteoarthritis
Looks at pain after robot-assisted knee replacement using a long-acting bupivacaine-meloxicam solution.
Key facts
- Who runs it
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- Where
- Cranberry Township, United StatesSee the site
- Trial code
- Registry title
- Post-Operative Pain Relief: Zynrelef or Periarticular Injections in RATKA
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 150 people, planned
- Started
- 3 Sept 2026
- Expected to end
- 28 Feb 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- bupivacaine-meloxicam (extended release)
- Bupivacaine
- Ketorolac
- Lidocaine (drug)
- Record updated
- 28 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with knee osteoarthritis who are scheduled for a robot-assisted total knee replacement (RATKA) on one knee. It compares two pain-relief injections given around the joint during surgery.
- Age
- 18 to 89 years
- Sex
- Males and females
- Disease stage
- Knee osteoarthritis (wear-and-tear arthritis) that needs surgery, with a planned robot-assisted total knee replacement on one knee only.
- Earlier treatment
- People who took more than 5 mg/day of opioid pain medicine for more than 1 month cannot join. People who had the other knee replaced less than 2 years before cannot join.
Main reasons for not taking part
- Children, pregnant people, or people in prison
- BMI of more than 45 kg/m2
- Long-term opioid use of >5 mg/day for >1 month
- Type 1 allergy to NSAIDs or local anesthetics
- Severe kidney disease
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Males or females aged 18-89 years
- Diagnosed with knee osteoarthritis requiring surgical intervention
- Indicated for unilateral RATKA
Who cannot take part
- History of contralateral TKA <2 years prior to the index TKA
- Prolonged opioid use history of >5 mg/day for >1 month
- Type 1 Hypersensitivity to NSAIDs or local anesthetics
- Diagnosis of severe renal disease
- Pediatric, pregnant, or incarcerated patients
- BMI of more than 45 kg/m2
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 89 years old?
Where in United States
- AHN Orthopedic Surgery Cranberry TownshipCranberry Township, United StatesContact: Andrew Waligora, MDTaking people
About the trial
What the trial wants to find out
Prospective Cohort of patients who are scheduled for a Robot Assisted Total Knee Arthroplasty (RATKA). A prospective survey of patient reported outcome measures (Numeric Rating Scale) will be obtained postoperatively of 72 hours, as well as at the postoperative opioid consumption after 72 hours.
The 2 groups in the trial
- ZynrelefTreatment being tested
Periarticular injection of bupivacaine-meloxicam extended release
Treatment: bupivacaine-meloxicam (extended release)
- ControlExisting treatment, for comparison
Periarticular injection of bupivacaine, ketorolac, and lidocaine
Treatment: Bupivacaine, Ketorolac, and Lidocaine (drug)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Postoperative Pain Outcomes After Use of Bupivacaine-Meloxicam Extended-Release Solution in Robot Assisted Total Knee Arthroplasty: A Prospective Study
- Plain-language title
- Pain relief after robot-assisted knee replacement for knee osteoarthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07430085, who can take part
- Record updated
- 28 October 2026